干旱区生态环境知识资源中心(Arid): Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

Arid

	Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial
	Chiron, David 1,2; Bellanger, Celine 1; Papin, Antonin 1; Tessoulin, Benoit ; Dousset, Christelle 1; Maiga, Sophie 1; Moreau, Anne 3; Esbelin, Julie 4; Trichet, Valerie 2,5; Chen-Kiang, Selina 6; Moreau, Philippe 7; Touzeau, Cyrille 7,8; Le Gouill, Steven 7,8; Amiot, Martine 1; Pellat-Deceunynck, Catherine 2,9
来源期刊	BLOOD
ISSN	0006-4971
EISSN	1528-0020
出版年	2016
卷号	128 期号:22
类型	Meeting Abstract
语种	英语
国家	France ; USA
收录类别	SCI-E ; CPCI-S
WOS记录号	WOS:000394446803099
WOS类目	Hematology
WOS研究方向	Hematology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/191845
作者单位	1.Univ Nantes, CNRS, CRCNA, INSERM, Nantes, France; 2.CNRS, GDR3697 Micronit, Nantes, France; 3.Nantes Univ Hosp, Dept Pathol, Nantes, France; 4.CHU, Serv Gynecol & Obster, Nantes, France; 5.Univ Nantes, LPRO, INSERM, Nantes, France; 6.Weill Cornell Med, Meyer Canc Ctr, New York, NY USA; 7.Nantes Univ Hosp, Dept Hematol, Nantes, France; 8.INSERM, UMR892, Nantes, France; 9.INSERM, CNRS, CRCNA, Nantes, France
推荐引用方式 GB/T 7714	Chiron, David,Bellanger, Celine,Papin, Antonin,et al. Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial[J],2016,128(22).
APA	Chiron, David.,Bellanger, Celine.,Papin, Antonin.,Tessoulin, Benoit.,Dousset, Christelle.,...&Pellat-Deceunynck, Catherine.(2016).Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial.BLOOD,128(22).
MLA	Chiron, David,et al."Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial".BLOOD 128.22(2016).